BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38185054)

  • 1. Camptothecin structure simplification elaborated new imidazo[2,1-b]quinazoline derivative as a human topoisomerase I inhibitor with efficacy against bone cancer cells and colon adenocarcinoma.
    Khodair AI; El-Hallouty SM; Cagle-White B; Abdel Aziz MH; Hanafy MK; Mowafy S; Hamdy NM; Kassab SE
    Eur J Med Chem; 2024 Feb; 265():116049. PubMed ID: 38185054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to camptothecin-like topoisomerase I inhibitors.
    Tomicic MT; Kaina B
    Biochim Biophys Acta; 2013 Jan; 1835(1):11-27. PubMed ID: 23006513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and biological assays of 9-(acylamino) homocamptothecins as DNA topoisomerase I inhibitors.
    Guo W; Dong G; Zhu L; Liu W; Zhuang C; Guo Z; Yao J; Sheng C; Zhang H; Miao Z; Zhang W
    Chem Biodivers; 2013 Oct; 10(10):1804-15. PubMed ID: 24130024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and Biological Evaluation of 10-Substituted Camptothecin Derivatives with Improved Water Solubility and Activity.
    Yang XY; Zhao HY; Lei H; Yuan B; Mao S; Xin M; Zhang SQ
    ChemMedChem; 2021 Mar; 16(6):1000-1010. PubMed ID: 33241878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topoisomerase I activity and sensitivity to camptothecin in breast cancer-derived cells: a comparative study.
    Tesauro C; Simonsen AK; Andersen MB; Petersen KW; Kristoffersen EL; Algreen L; Hansen NY; Andersen AB; Jakobsen AK; Stougaard M; Gromov P; Knudsen BR; Gromova I
    BMC Cancer; 2019 Nov; 19(1):1158. PubMed ID: 31783818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topoisomerase I-mediated DNA cleavage as a guide to the development of antitumor agents derived from the marine alkaloid lamellarin D: triester derivatives incorporating amino acid residues.
    Tardy C; Facompré M; Laine W; Baldeyrou B; García-Gravalos D; Francesch A; Mateo C; Pastor A; Jiménez JA; Manzanares I; Cuevas C; Bailly C
    Bioorg Med Chem; 2004 Apr; 12(7):1697-712. PubMed ID: 15028262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring DNA topoisomerase I ligand space in search of novel anticancer agents.
    Drwal MN; Agama K; Wakelin LP; Pommier Y; Griffith R
    PLoS One; 2011; 6(9):e25150. PubMed ID: 21966440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Novel Camptothecin Derivative 3j Inhibits Nsclc Proliferation Via Induction of Cell Cycle Arrest By Topo I-Mediated DNA Damage.
    Liu Y; Zhang J; Feng S; Zhao T; Li Z; Wang L; Wang P; Du H; Yuan S; Sun L
    Anticancer Agents Med Chem; 2019; 19(3):365-374. PubMed ID: 30523769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of 13H-benzo[f]chromeno[4,3-b][1,7]naphthyridines and their salts as potent cytotoxic agents and topoisomerase I/IIα inhibitors.
    Arepalli SK; Lee C; Sim S; Lee K; Jo H; Jun KY; Kwon Y; Kang JS; Jung JK; Lee H
    Bioorg Med Chem; 2018 Oct; 26(18):5181-5193. PubMed ID: 30253887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insight on the Interaction between the Camptothecin Derivative and DNA Oligomer Mimicking the Target of Topo I Inhibitors.
    Bocian W; Naumczuk B; Urbanowicz M; Sitkowski J; Bednarek E; Wiktorska K; Pogorzelska A; Wielgus E; Kozerski L
    Molecules; 2022 Oct; 27(20):. PubMed ID: 36296539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evodiamine, a dual catalytic inhibitor of type I and II topoisomerases, exhibits enhanced inhibition against camptothecin resistant cells.
    Pan X; Hartley JM; Hartley JA; White KN; Wang Z; Bligh SW
    Phytomedicine; 2012 May; 19(7):618-24. PubMed ID: 22402246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural insight of DNA topoisomerases I from camptothecin-producing plants revealed by molecular dynamics simulations.
    Sirikantaramas S; Meeprasert A; Rungrotmongkol T; Fuji H; Hoshino T; Sudo H; Yamazaki M; Saito K
    Phytochemistry; 2015 May; 113():50-6. PubMed ID: 25733498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and evaluation of thiohydantoin derivatives as potent topoisomerase I (Top1) inhibitors with anticancer activity.
    Majumdar P; Bathula C; Basu SM; Das SK; Agarwal R; Hati S; Singh A; Sen S; Das BB
    Eur J Med Chem; 2015 Sep; 102():540-51. PubMed ID: 26312433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human topoisomerase I inhibition: docking camptothecin and derivatives into a structure-based active site model.
    Laco GS; Collins JR; Luke BT; Kroth H; Sayer JM; Jerina DM; Pommier Y
    Biochemistry; 2002 Feb; 41(5):1428-35. PubMed ID: 11814334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and biological activities of two camptothecin derivatives against Spodoptera exigua.
    Yang F; Wang L; Zhang L; Zhang Y; Mao L; Jiang H
    Sci Rep; 2019 Dec; 9(1):18067. PubMed ID: 31792297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecin-resistant topoisomerases I.
    Antony S; Jayaraman M; Laco G; Kohlhagen G; Kohn KW; Cushman M; Pommier Y
    Cancer Res; 2003 Nov; 63(21):7428-35. PubMed ID: 14612542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human topoisomerase I mediates illegitimate recombination leading to DNA insertion into the ribosomal DNA locus in Saccharomyces cerevisiae.
    Zhu J; Schiestl RH
    Mol Genet Genomics; 2004 Apr; 271(3):347-58. PubMed ID: 15007730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homocamptothecin, an E-ring-modified camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditions.
    Philippart P; Harper L; Chaboteaux C; Decaestecker C; Bronckart Y; Gordover L; Lesueur-Ginot L; Malonne H; Lavergne O; Bigg DC; da Costa PM; Kiss R
    Clin Cancer Res; 2000 Apr; 6(4):1557-62. PubMed ID: 10778989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular and cellular pharmacology of the novel noncamptothecin topoisomerase I inhibitor Genz-644282.
    Sooryakumar D; Dexheimer TS; Teicher BA; Pommier Y
    Mol Cancer Ther; 2011 Aug; 10(8):1490-9. PubMed ID: 21636699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo sequencing of camptothecin-induced topoisomerase I cleavage sites in human colon carcinoma cells.
    Pondarré C; Strumberg D; Fujimori A; Torres-León R; Pommier Y
    Nucleic Acids Res; 1997 Oct; 25(20):4111-6. PubMed ID: 9321666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.